Methods for producing nateglinide B-type crystals,Process for preparing nateglinide and intermediates thereof,Crystalline form of nateglinide,Crystalline form of nateglinide,Polymorphic forms of nateglinide

Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

35 results about "Nateglinide" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Nateglinide is used alone or with other medications to control high blood sugar along with a proper diet and exercise program. It is used in people with type 2 diabetes.

Methods for producing nateglinide B-type crystals

InactiveUS7544834B2Low costMetabolism disorderOrganic compound preparationSolventIndustrial scale

A method for producing B-type crystals of nateglinide substantially free of H-type crystals is provided, which comprises drying solvated wet crystals of nateglinide at a low temperature until no solvent remains and making a crystal conversion thereof. According to this method, B-type crystals of nateglinide can be produced at an industrial scale without allowing other forms of the crystalline polymorphism to coexist.

Owner:AJINOMOTO CO INC

Process for preparing nateglinide and intermediates thereof

InactiveUS6861553B2BiocidePeptide/protein ingredientsIsopropylcyclohexaneD-Phenylalanine

Provided is a process for preparation of an intermediate in the synthesis of nateglinide. Trans-4-isopropylcyclohexane acid chloride is formed by reacting 4-isopropylcyclohexanecarboxyl acid with thionyl chloride in the presence of an effective amount of an organic amide.Also provided are processes for preparation of nateglinide by acylation of a suitable salt of D-phenylalanine with trans-4-isopropylcyclohexane acid chloride in both a single and a two phase system, and in water free of a co-solvent.

Process for preparing nateglinide and intermediates thereof

View all

Owner:TEVA PHARM USA INC

Crystalline form of nateglinide

InactiveUS7534913B2BiocidePeptide/protein ingredientsPharmaceutical formulationMedicinal chemistry

Provided are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

View all

Owner:TEVA PHARM USA INC

Crystalline form of nateglinide

InactiveUS20050014836A1BiocidePeptide/protein ingredientsPharmaceutical formulationMedicinal chemistry

View all

Owner:TEVA PHARM USA INC

Polymorphic forms of nateglinide

InactiveCN1723190AMetabolism disorderCarboxylic acid amide separation/purificationGreek letter epsilonPharmaceutical formulation

Provided are crystalline forms of nateglinide, labeled forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, alpha, beta, gamma, delta, epsilon, sigma, theta and omega, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

View all

Owner:TEVA PHARMA IND LTD

Polymorphic forms of nateglinide

InactiveUS20050090552A1BiocidePeptide/protein ingredientsPharmaceutical formulationMedicinal chemistry

Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, 0, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

View all

Owner:TEVA PHARMA IND LTD +1

Nateglinide tablet and preparation method thereof

InactiveCN101612133ARapid disintegration of the drugQuality improvementOrganic active ingredientsMetabolism disorderCarboxymethyl starchAdditive ingredient

The invention relates to Nateglinide tablets and a preparation method thereof; in Nateglinide, 30-60% of filler is 3-15% of starch and 10-30% of microcrystalline cellulose, bonding agent is 1-10% of low substituted hydroxypropyl methylcellulose, disintegrant is 15-50% of sodium carboxymethyl starch, fluidizer is 0.1-5% of silica, and lubricant is 0.1-1% of magnesium stearate; the preparation method comprises the following steps: sieving raw materials for standby use; weighing Nateglinide with prescription amount, adding appropriate purified water, blending to prepare soft material, pelletizing and drying to prepare granules of main drug; evenly mixing microcrystalline cellulose, starch and part of sodium carboxymethyl starch, adding substituted hydroxypropyl methylcellulose by equivalently progressive method, evenly mixing to prepare soft material, pelletizing and drying; mixing granules of main drug with granules of accessories, adding residual sodium carboxymethyl starch, magnesium stearate and silica to be evenly mixed, pelletizing and tabletting. The invention has the characteristics of few components, available accessories, capability of fully disintegration in 3 minutes, above 95% of dissolution rate and suitability for long term storage.

Owner:JIANGSU WANBANG BIOPHARMLS +1

Methods for producing nateglinide crystals

InactiveUS7208622B2Organic compound preparationCarboxylic acid amide separation/purificationD-PhenylalanineKetone solvents

There is provided methods for producing nateglinide crystals, which comprises the steps of adding an acid(s) to a reaction mixture containing nateglinide to make it acidic, the reaction mixture being obtained by reacting trans-4-isopropylcyclohexylcarbonyl chloride with D-phenylalanine in a mixed solvent of ketone solvent and water in the presence of an alkali; and then adjusting the temperature of the mixture to 58° C. to 72° C. and the concentration of ketone solvent to more than 8 wt % and less than 22 wt % to conduct precipitation of nateglinide crystals. This producing method is the industrially beneficial methods for crystallization of nateglinide.

Owner:AJINOMOTO CO INC

Antidiabetic preparation for oral administration

InactiveUS7022339B2Organic active ingredientsPowder deliveryImmediate releaseBuccal administration

There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.

Antidiabetic preparation for oral administration

View all

Owner:AJINOMOTO CO INC

Nateglinide-containing preparation

InactiveUS7605180B2Organic active ingredientsBiocideDiabetes mellitusImmediate release

The present invention discloses, as a immediate-release preparation useful as an antidiabetic, a nateglinide-containing preparation comprising nateglinide as an active ingredient wherein the nateglinide is amorphous.

View all

Owner:AJINOMOTO CO INC

Polymorphic forms of nateglinide

InactiveUS20060004102A1Lower blood sugar levelsBiocidePeptide/protein ingredientsMedicinal chemistryCrystallization

Provided are crystalline forms of nateglinide and processes for their preparation.

View all

Owner:TEVA PHARM USA INC

Polymorphic forms of nateglinide

InactiveUS20050014949A1Organic active ingredientsOrganic compound preparationPharmaceutical formulationMedicinal chemistry

Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

View all

Owner:TEVA PHARM USA INC

Polymorphic forms of nateglinide

InactiveUS20080319075A1BiocidePeptide/protein ingredientsPharmaceutical formulationMedicinal chemistry

View all

Owner:YAHALOMI RONIT +5

Polymorphic forms of nateglinide

InactiveUS20050075400A1Organic active ingredientsBiocidePharmaceutical formulationMedicinal chemistry

View all

Owner:TEVA PHARMA IND LTD +1

Synthesis of pharmaceutical

InactiveCN101190887ALow costOrganic compound preparationCarboxylic acid amides preparationD-PhenylalanineSynthesis methods

The invention relates to a synthesis method of a nateglinide, in particular to the synthesis of the nateglinide by a one-pot method. Original material D-phenylalanine is used as raw material in the method, D-phenylalanine esterified substance (II) is obtained through esterification, a compound (IV) is obtained through acylation of isopropylcyclohexanecarboxylic acid (III), and then the compound (IV) is ester hydrolyzed so as to obtain the nateglinide. The technique of the method has simple technique process and easy and convenient post-treatment; meanwhile, the method has the advantages of strong operability, being easy to be industrialized and cost saving.

View all

Owner:TIANJIN PHARMA GROUP CORP

Polymorphic forms of nateglinide

InactiveUS7420084B2Organic compound preparationOrganic chemistry methodsPharmaceutical formulationMedicinal chemistry

View all

Owner:TEVA PHARM USA INC

Solid compound of dapagliflozin as well as preparation method and application of solid compound

PendingCN114671839AOrganic active ingredientsMetabolism disorderCandesartanBULK ACTIVE INGREDIENT

The invention discloses a dapagliflozin solid-form compound as well as a preparation method and application thereof. The compound is in a solid form formed by dapagliflozin, nateglinide, candesartan cilexetil, anagliptin or enalapril. The invention also comprises a preparation method and application of the dapagliflozin solid compound. According to the dapagliflozin solid compound, the two components are combined in a hydrogen bond or other non-covalent bond mode on the basis that original molecular covalent bonds are not damaged, a new eutectic or amorphous substance is formed, the two active components exist in a specific stoichiometric ratio, no organic solvent is contained, and the preparation method is simple. And good biocompatibility is achieved. Different from a mixture obtained by simply and physically mixing the two active ingredients, the compound provided by the invention can effectively improve various physicochemical properties of the medicine, improve the stability, solubility and bioavailability of the medicine and effectively improve the hygroscopicity of the medicine.

Solid compound of dapagliflozin as well as preparation method and application of solid compound

View all

Owner:HINYE PHARM CO LTD

Polymorphic forms of nateglinide

InactiveUS20070004804A1Organic active ingredientsBiocidePharmaceutical formulationMedicinal chemistry

Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, 0, P, Q, T, U, V, Y, α, β, γ, δ, ε, δ, σ, 2 and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.

View all

Owner:TEVA PHARM USA INC

Nateglinide-containing preparation

InactiveUS20090203791A1High dissolution rateBiocideOrganic active ingredientsDiabetes mellitusImmediate release

View all

Owner:AJINOMOTO CO INC

Polymorphic forms of nateglinide

InactiveUS7358390B2Organic active ingredientsOrganic compound preparationPharmaceutical formulationMedicinal chemistry

View all

Owner:TEVA PHARM USA INC

Green food for treating diabetes and preparation process thereof

PendingCN110973603AGuaranteed contentFood ingredient functionsBiotechnologyNutrients substances

The invention discloses a green food for treating diabetes and a preparation process thereof, and belongs to the technical field of foods. The preparation process comprises the following steps: dryingand grinding oat, radix puerariae, Chinese yams, coix seeds, konjak, Chinese wolfberry fruits and other components respectively to obtain oat powder, radix puerariae powder, Chinese yam powder, coixseed powder, konjak powder and Chinese wolfberry fruit powder; carrying out biological extraction on oat beta glucose and a polygonatum sibiricum extract, and drying at low temperature to obtain oat beta glucose particles and polygonatum kingianum extract particles; and mixing oat powder, radix puerariae powder, Chinese yam powder, coix seed powder, konjaku flour, Chinese wolfberry fruit powder, oat beta glucose particles and polygonatum kingianum extract particles to obtain the green food. The total content of the oat powder and the cooked Chinese yams exceeds 50%; it is ensured that the content of metformin and nateglinide satisfies the function of treating and inhibiting diabetes mellitus; the fineness of the oat powder and the cooked Chinese yam is 320-350 meshes; and the cell wall breaking rate of the oat powder and the cooked Chinese yam is greater than 90%, so that respective nutrient substances are effectively amplified, and the absorption rate of people reaches 90% or above.

Owner:苏州隆欣达生物科技有限公司

Method for separating nateglinide and its stereoisomers by high performance liquid chromatography

ActiveCN107505410BAchieve separationRealize determinationComponent separationCarbamateSilica gel

The invention discloses an HPLC (high performance liquid chromatography) resolution method for nateglinide and nateglinide stereoisomers. The method comprises the following steps: dissolving a mixed sample containing nateglinide as well as a cis-isomer and an L-isomer of nateglinide in a diluent until the concentration reaches 0.1-2 mg / mL; resolving nateglinide and the nateglinide stereoisomers with an HPLC system by taking silica gel with surface in covalent bonding with amylose-tris(3-chloro-methylphenyl carbamate) as a stationary phase. Nateglinide as well as the cis-isomer and the L-isomer of nateglinide can be resolved rapidly, efficiently and simultaneously with the method. The separation efficiency is high, the resolution time is short, the separation degree between the cis-isomer of nateglinide and nateglinide is 3.82, the separation degree between the L-isomer of nateglinide and nateglinide is 9.84, the method for simultaneously separating nateglinide from the cis-isomer and the L-isomer of nateglinide and determining nateglinide as well as the cis-isomer and the L-isomer of nateglinide is realized effectively, and effectiveness and safety of nateglinide products are guaranteed.

Method for separating nateglinide and its stereoisomers by high performance liquid chromatography

View all

Owner:JIANGSU DEYUAN PHARMA

Compound nateglinide valsatan medicinal composition

InactiveCN101756962BLow dissolution rateMetabolism disorderPill deliveryValsartanImmediate release

The invention relates to a compound nateglinide valsatan medicinal composition, which is a dual-layer tablet and comprises a first layer of nateglinide and a second layer of valsatan, wherein the first layer is delivered from a self-soluble tablet to be immediately released; and the second layer is released from a self-disintegration or corroded tablet matrix.

View all

Owner:TIANJIN HANKANG PHARMA BIOTECH

Process for preparing nateglinide and intermediates thereof

InactiveCN100384813COrganic compound preparationOrganic chemistry methodsIsopropylcyclohexaneAcyl group

Provided is a method for preparing an intermediate in the synthesis of nateglinide. Trans-4-isopropylcyclohexane acid chloride is formed by reacting 4-isopropylcyclohexanecarboxylic acid with thionyl chloride in the presence of an effective amount of an organic amide. Also provided is the acylation of a suitable salt of D-phenylalanine with trans-4-isopropylcyclohexane acid chloride in single-phase and two-phase systems and in water free of co-solvents to prepare Nagar Lennet's method.

View all

Owner:TEVA PHARMA IND LTD

New crystal type of netoglitazone and preparation method thereof

InactiveCN101037420BImprove stabilitySimple processOrganic active ingredientsOrganic chemistryDiabetes mellitusMedicine

Crystal form of nateglinide and its producing method are provided, relating to the chemical medicine field, especially to the medicine for treating diabetes. The X-radial powder diffraction spectrum of the crystal form of nateglinide has absorption peak at 14.9+-0.2, 17.3+-0.2, 18.4+-0.2, 19.0+-0.2, 19.5+-0.2, 20.4+-0.2, 22.1+-0.2, 24.2+-0.2, 25.2+-0.2, 26.7+-0.2, 27.7+-0.2 which is represented by 2theta. Crystal form of nateglinide has an absorption single peak at 148+-0.3 DEG C measured by DSC. The infra-red spectrum of the crystal form of nateglinide has absorption peak at 1757+-3cm-1, 1688+-3cm-1, 981+-1cm-1, 767+-1cm-1. The nateglinide F-crystal form has a good stability and can be produced in a large scale. The nateglinide F-crystal form produced from the complex form has a simple art, a convenient operation, and a similar drug action with the known nateglinide A-crystal form and does not gain special equipments.

New crystal type of netoglitazone and preparation method thereof

View all

Owner:GUANGZHOU PHARMACEUTICAL INDUSTRIAL RESEARCH INSTITUTE

Process for the preparation of nateglinide

InactiveUS9150499B2High yieldHigh purityMetabolism disorderOrganic compound preparationD-PhenylalanineEnantiomer

The present invention relates to a process for the preparation of substantially pure nateglinide of formula (I), substantially free from the cis-isomer and L-enantiomer and preparation of enantiomerically pure nateglinide form B, directly from the hydrolysis of a (−)-N-(trans-4-isopropylcyclohexyl-1-carbonyl)-D-phenylalanine alkyl ester in a ketonic solvent or water or mixture thereof.

Process for the preparation of nateglinide

View all

Owner:CIPLA LTD

Nateglinide tablet and method for preparing nateglinide tablet through direct compression method

InactiveCN105534931ALess prone to numbnessNot prone to splintersOrganic active ingredientsMetabolism disorderMedicineCompression method

The invention discloses a nateglinide tablet and a method for preparing the nateglinide tablet through a direct compression method, wherein each one thousand of nateglinide tablets are prepared from 30g of nateglinide, 45g of diluent, 35g of disintegrating agent, 1g of lubricating agent and 3g of flow aid, the preparation method for preparing the nateglinide tablet through direct compression by using a compressible auxiliary material comprises a process of weighing and matching, screening, mixing, tabletting, inner packing and packing under the D level condition, the nateglinide tablet and the method, provided by the invention solve the problems of cracking tablet, rough tablet, sticking and the like of a nateglinide tablet prepared through a traditional wet method.

Nateglinide tablet and method for preparing nateglinide tablet through direct compression method

View all

Owner:ANHUI GLOBAL PHARM CO LTD

Compound nateglinide valsatan medicinal composition

InactiveCN101756962ALow dissolution rateMetabolism disorderPill deliveryValsartanMedicine

View all

Owner:TIANJIN HANKANG PHARMA BIOTECH

Stable Nateglinide Form B Compositions

InactiveUS20080096970A1Without any changeOrganic active ingredientsBiocideSolventHydrocarbon

A process for preparing nateglinide Form B comprises dissolving nateglinide in a solvent and adding the solution, at temperatures of 40-45° C., to a hydrocarbon liquid that is at temperatures of 40-45° C. Then, water is added and the mixture is allowed to cool, producing crystals of nateglinide Form B.

View all

Owner:DR REDDYS LAB LTD +1

Additive for improving plasticity of plastic

InactiveCN106832765AImprove plasticityIncrease the tensile stressEpoxyMonopotassium phosphate

The invention discloses an additive for improving plastic plasticity, which comprises the following components according to the ratio of parts by weight: 20-40 parts of potassium sulfate solution, and 12-20 parts of modified glycerin epoxy resin , 0.3-0.7 parts of sodium carbonate, 0.01-0.03 parts of ammonium chloride, 0.01-0.02 parts of methyl formate, 0.1-0.4 parts of regulator, 0.02-0.03 parts of nateglinide and 1-3 parts of potassium dihydrogen phosphate. The additive for improving the plasticity of the present invention can effectively improve the plasticity of the plastic, increase its transverse and longitudinal tensile stress, so that the plastic has a better plasticizing effect; further, the raw materials of the present invention are easy to obtain, and the preparation method is simple and easy. operate.

Owner:南宁市钜丰塑业有限公司

35 results about "Nateglinide" patented technology

Popular searches